Keytruda + Padcev reduced risk of EFS and death for muscle-invasive bladder cancer when given before and after surgery

Catheter with specialized nanosensors could enable earlier detection of bladder cancer, MIT study finds

While treatment is often successful, bladder cancer has one of the highest rates of recurrence of any cancer: Following treatment, about 50% of patients develop tumors again within the next five years. This makes it one of the most expensive cancers for society to treat.

June 05, 2026

Vol.52 No.22

Drugs & Targets

FDA approves durvalumab in combination with Bacillus Calmette-Guerin for high-risk non-muscle invasive bladder cancer

FDA approved Imfinzi (durvalumab) in combination with Bacillus Calmette-Guerin for the treatment of adult patients with BCG-naïve, high-risk non-muscle invasive bladder cancer.

June 05, 2026

Vol.52 No.22

Clinical Roundup

Imfinzi regimen reduced early disease recurrence in non-muscle-invasive bladder cancer, phase III trial POTOMAC shows

Exploratory analyses of the POTOMAC phase III trial showed adding one year of treatment with AstraZeneca’s Imfinzi (durvalumab) to BCG induction and maintenance therapy reduced the number of high-risk disease recurrences within the first year, with fewer BCG-unresponsive recurrences in patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer compared to BCG treatment alone.

May 22, 2026

Vol.52 No.20

Clinical Roundup

Perioperative Imfinzi + neoadjuvant EV improved EFS and OS in muscle-invasive bladder cancer, phase III VOLGA trial shows

High-level results from a planned interim analysis of the VOLGA phase III trial showed perioperative treatment with Imfinzi (durvalumab) in combination with neoadjuvant enfortumab vedotin demonstrated statistically significant and clinically meaningful improvements in event-free survival and overall survival in patients with muscle-invasive bladder cancer versus standard of care.

May 22, 2026

Vol.52 No.20

Drugs & Targets

FDA approves Signatera CDx as a companion diagnostic in muscle-invasive bladder cancer

FDA approved Signatera CDx as a companion diagnostic for use with adjuvant atezolizumab (Tecentriq) immunotherapy in muscle-invasive bladder cancer.

May 22, 2026

Vol.52 No.20

Drugs & Targets

FDA approves label update to accelerate thaw time for Adstiladrin gene therapy for NMIBC

FDA approved a label update that will accelerate thaw time for Adstiladrin (nadofaragene firadenovec-vncg), gene therapy for adults with high-risk, BCG-unresponsive non-muscle invasive bladder cancer, enabling an accelerated water-bath thawing method, completed in about 25 minutes, to enhance efficient clinical preparation for healthcare teams.

March 27, 2026

Vol.52 No.12

Keytruda + Padcev reduced risk of EFS and death for muscle-invasive bladder cancer when given before and after surgery

YOU MAY BE INTERESTED IN

Catheter with specialized nanosensors could enable earlier detection of bladder cancer, MIT study finds

FDA approves durvalumab in combination with Bacillus Calmette-Guerin for high-risk non-muscle invasive bladder cancer

Imfinzi regimen reduced early disease recurrence in non-muscle-invasive bladder cancer, phase III trial POTOMAC shows

Perioperative Imfinzi + neoadjuvant EV improved EFS and OS in muscle-invasive bladder cancer, phase III VOLGA trial shows

FDA approves Signatera CDx as a companion diagnostic in muscle-invasive bladder cancer

FDA approves label update to accelerate thaw time for Adstiladrin gene therapy for NMIBC

Renew today!

Subscriber content

Never miss an issue!

Login